Earth Science Tech Inc. (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, has completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (APIs) and finished FDA-approved prescription products. This move is poised to deliver value across three growth drivers: expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market.
The acquisition of Zoolzy, which operates from a 3,684-square-foot facility in Doral, Florida, is a calculated step by Earth Science Tech to seize strategic opportunities that broaden its telehealth and pharmacy fulfillment platforms into new, complementary verticals. By integrating Zoolzy's distribution capabilities, ETST's compounding pharmacies can secure essential raw materials at highly competitive wholesale pricing, significantly increasing the company's overall profit margins.
According to the company, this acquisition not only enhances its existing operations but also expands its reach into the veterinary market, a sector with growing demand for pharmaceutical products. The move reflects Earth Science Tech's commitment to diversifying its revenue streams and strengthening its position in the healthcare industry.
Investors and industry observers are taking note of this strategic expansion, as it aligns with broader trends in the pharmaceutical supply chain where vertical integration and cost efficiency are becoming increasingly important. By securing direct access to APIs and finished products, Earth Science Tech can better control its supply chain, reduce costs, and improve service delivery to its customers.
For more information on Earth Science Tech and its recent developments, visit the company's newsroom at https://ibn.fm/ETST. Additional details about the acquisition can be found at https://ibn.fm/vcqkE.
This acquisition is a clear indication that Earth Science Tech is actively pursuing growth opportunities that leverage its existing infrastructure while entering new markets. As the company continues to evolve, it remains focused on delivering value to shareholders and expanding its footprint in the healthcare and pharmaceutical sectors.
